Additionally, we found that anti-VEGF and EGFR antibodies could not only reduce CRC cells proliferation and invasion in vitro, but also inhibit the tumor growth and angiogenesis in vivo mainly through prohibiting the activation of AKT and ERK signaling pathways. The gene discussed is AKT1; the disease is colorectal carcinoma.